Orchid Pharma [ORCHPHARMA] vs Healthcare Global [HCG] Detailed Stock Comparison
Orchid Pharma
NSE
Loading...
Healthcare Global
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Orchid Pharma wins in 9 metrics, Healthcare Global wins in 10 metrics, with 0 ties. Healthcare Global appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Orchid Pharma | Healthcare Global | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 42.55 | 264.20 | Orchid Pharma |
| Price-to-Book Ratio | 2.85 | 10.42 | Orchid Pharma |
| Debt-to-Equity Ratio | 13.78 | 185.57 | Orchid Pharma |
| PEG Ratio | -0.86 | -4.34 | Healthcare Global |
| EV/EBITDA | 36.34 | 26.80 | Healthcare Global |
| Profit Margin (TTM) | 10.02% | 1.61% | Orchid Pharma |
| Operating Margin (TTM) | 3.19% | 8.14% | Healthcare Global |
| EBITDA Margin (TTM) | 3.19% | 8.14% | Healthcare Global |
| Return on Equity | 7.86% | 4.49% | Orchid Pharma |
| Return on Assets (TTM) | 5.90% | 1.25% | Orchid Pharma |
| Free Cash Flow (TTM) | $-1.31B | $1.08B | Healthcare Global |
| 1-Year Return | -53.83% | 64.07% | Healthcare Global |
| Price-to-Sales Ratio (TTM) | 4.26 | 4.18 | Healthcare Global |
| Enterprise Value | $36.10B | $112.07B | Healthcare Global |
| EV/Revenue Ratio | 4.24 | 4.85 | Orchid Pharma |
| Gross Profit Margin (TTM) | 42.83% | 51.80% | Healthcare Global |
| Revenue per Share (TTM) | $168 | $166 | Orchid Pharma |
| Earnings per Share (Diluted) | $16.75 | $2.62 | Orchid Pharma |
| Beta (Stock Volatility) | 1.73 | -0.12 | Healthcare Global |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Orchid Pharma vs Healthcare Global Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Orchid Pharma | 0.68% | -3.01% | -6.37% | -2.95% | -23.06% | -61.49% |
| Healthcare Global | -0.59% | 3.41% | 12.45% | 25.19% | 38.18% | 43.09% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Orchid Pharma | -53.83% | 111.00% | 12,869.72% | 1,213.85% | 249.06% | 185.19% |
| Healthcare Global | 64.07% | 163.23% | 469.32% | 296.34% | 296.34% | 296.34% |
News Based Sentiment: Orchid Pharma vs Healthcare Global
Orchid Pharma
News based Sentiment: MIXED
The month presented a mixed picture for Orchid Pharma, with disappointing Q1 results countered by significant strategic developments like the Enmetazobactam acquisition and a substantial fundraising plan. These developments suggest a proactive approach to long-term growth despite current market challenges, making it a noteworthy month for investors.
Healthcare Global
News based Sentiment: POSITIVE
HCG demonstrated strong financial performance with a 17% YoY increase in oncology revenue and continued progress on the KKR acquisition. While the CFO resignation introduces some uncertainty, the company's overall trajectory remains positive, supported by strategic initiatives and a clear growth strategy.
Performance & Financial Health Analysis: Orchid Pharma vs Healthcare Global
| Metric | ORCHPHARMA | HCG |
|---|---|---|
| Market Information | ||
| Market Cap | ₹36.16B | ₹96.68B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 38,535 | 170,426 |
| 90 Day Avg. Volume | 63,705 | 226,982 |
| Last Close | ₹711.65 | ₹689.90 |
| 52 Week Range | ₹603.80 - ₹1,997.40 | ₹390.95 - ₹708.00 |
| % from 52W High | -64.37% | -2.56% |
| All-Time High | ₹2,654.25 (Apr 05, 2021) | ₹708.00 (Sep 03, 2025) |
| % from All-Time High | -73.19% | -2.56% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.29% | 0.17% |
| Quarterly Earnings Growth | -0.49% | -0.61% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.02% |
| Operating Margin (TTM) | 0.03% | 0.08% |
| Return on Equity (TTM) | 0.08% | 0.04% |
| Debt to Equity (MRQ) | 13.78 | 185.57 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹250.11 | ₹66.43 |
| Cash per Share (MRQ) | ₹35.44 | ₹24.89 |
| Operating Cash Flow (TTM) | ₹-82,697,000 | ₹831.60M |
| Levered Free Cash Flow (TTM) | ₹996.57M | ₹444.10M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Orchid Pharma vs Healthcare Global
| Metric | ORCHPHARMA | HCG |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 42.55 | 264.20 |
| Forward P/E | 21.94 | 149.83 |
| PEG Ratio | -0.86 | -4.34 |
| Price to Sales (TTM) | 4.26 | 4.18 |
| Price to Book (MRQ) | 2.85 | 10.42 |
| Market Capitalization | ||
| Market Capitalization | ₹36.16B | ₹96.68B |
| Enterprise Value | ₹36.10B | ₹112.07B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.24 | 4.85 |
| Enterprise to EBITDA | 36.34 | 26.80 |
| Risk & Other Metrics | ||
| Beta | 1.73 | -0.12 |
| Book Value per Share (MRQ) | ₹250.11 | ₹66.43 |
Financial Statements Comparison: Orchid Pharma vs Healthcare Global
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ORCHPHARMA | HCG |
|---|---|---|
| Revenue/Sales | ₹2.37B | ₹5.83B |
| Cost of Goods Sold | ₹1.38B | ₹2.83B |
| Gross Profit | ₹994.63M | ₹3.00B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹683.48M | ₹476.50M |
| EBITDA | ₹318.81M | ₹1.16B |
| Pre-Tax Income | ₹190.94M | ₹136.20M |
| Income Tax | ₹-394,000 | ₹68.50M |
| Net Income (Profit) | ₹222.95M | ₹67.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ORCHPHARMA | HCG |
|---|---|---|
| Cash & Equivalents | ₹211.07M | ₹2.36B |
| Total Current Assets | ₹8.07B | ₹8.44B |
| Total Current Liabilities | ₹2.86B | ₹10.46B |
| Long-Term Debt | ₹1.32B | ₹13.80B |
| Total Shareholders Equity | ₹12.67B | ₹9.90B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹6.32B | ₹19.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ORCHPHARMA | HCG |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ORCHPHARMA | HCG |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 38,535 | 170,426 |
| Average Daily Volume (90 Day) | 63,705 | 226,982 |
| Shares Outstanding | 50.72M | 139.42M |
| Float Shares | 15.19M | 39.29M |
| % Held by Insiders | 0.70% | 0.81% |
| % Held by Institutions | 0.20% | 0.12% |
Dividend Analysis & Yield Comparison: Orchid Pharma vs Healthcare Global
| Metric | ORCHPHARMA | HCG |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | ₹0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |